top of page

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of thoracic medical oncologist Heather A. Wakelee, MD, FASCO to the OncoC4 Scientific Advisory Board (SAB) made up of distinguished scientists, industry experts, and key opinion leaders in oncology and immunotherapy. Dr. Wakelee, currently a Professor of Medicine and Chief of the Division of Oncology at Stanford University, and Deputy Director of the Stanford Cancer Institute, brings over 20 years of experience in clinical strategy. OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

Aktuelle Beiträge

Alle ansehen

Comments


bottom of page